Minerva Neurosciences Inc Q3 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Just wondering -- probably for RTmy, the differences between the significant results you saw on the PSP, and unfortunately, the endpoint that slightly missed on the Marder NSFS, have you done further analysis to fully understand what the Marder scale may be capturing or not capturing that isn't reflected in the PSP or vice versa? I'm trying to understand what components crossover and what don't, so that you and also the regulators can get a better sense of what efficacy components are important for this drug? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 02, 2020 / 1:30PM, NERV.OQ - Q3 2020 Minerva Neurosciences Inc Earnings Call

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : No, that's helpful. And then maybe one for Geoff. I guess as you think of best case scenarios coming out of this meeting being proceed to filing versus running another trial versus something else. How do you think about the differential near-term capital needs for the company and getting that over the line. And also can you -- is there any cause to opt back into the seltorexant program when you opted out? Or is that completely off the table now that Janssen's proceeded in the Phase III trials?